Cisapride, before and after: still waiting for ADE-reporting reform

Sibbald, Barbara
November 2001
CMAJ: Canadian Medical Association Journal;11/13/2001, Vol. 165 Issue 10, p1370
Academic Journal
Focuses on the efforts of Health Canada to improve the country's prescription drug monitoring system. Mention of recommendations made after an inquest into the death of a teenager from the antireflux drug cisapride; Health Canada's request for a merger of the adverse drug event reporting systems of Canada and the United States; Perceived problems with voluntary, rather than mandatory, reporting of adverse drug events.


Related Articles

  • Canadian ADR reports up in 2003.  // Reactions Weekly;4/24/2004, Issue 998, p3 

    Focuses on the reports received by Health Canada regarding suspected adverse drug reactions (ADR) in 2003. Percentage of the reports which were classified as serious; Increase in the number of ADR cases reported since 1998; Origin of the reports.

  • Adverse reaction reporting could save lives.  // Canadian Nurse;Oct2006, Vol. 102 Issue 8, p7 

    The article focuses on the efforts by Health Canada Co. to improve patient health and safety through its adverse reaction reporting program. The company has made it simpler to report incidents of adverse reactions with the online posting of its adverse reaction reporting forms. The company's web...

  • Online reporting of adverse reactions. Sibbald, Barbara // CMAJ: Canadian Medical Association Journal;9/12/2006, Vol. 175 Issue 6, p582 

    The article presents information on an online reporting system launched by Health Canada Co. Adverse reaction reports can now be filed by physicians with Health Canada at www.hc-sc.gc.ca/dhp-mps/medeff/report-declaration/index_e.html. The online reporting system will make it more easier and...

  • Report adverse reactions to Health Canada.  // British Columbia Medical Journal;Jun2013, Vol. 55 Issue 5, p233 

    The article announces that Health Canada is asking people to report a serious or unexpected adverse reaction because of any health product.

  • Sibutramine use in contraindicated conditions continues.  // Reactions Weekly;10/20/2007, Issue 1174, p3 

    This article states that Health Canada is receiving reports of cardiovascular adverse reactions associated with sibutramine use among patients who have contraindications. Health Canada has received 65 reports of such adverse reactions between January 2001 and May 2007. 13 of these reports...

  • Keeping Tabs on Drug Reactions. O'Grady, Kathleen // Herizons;Summer2003, Vol. 17 Issue 1, p16 

    PharmaWatch and Women and Health Protection, two of Canada's top advocacy groups to keep pharmaceutical companies in check, are pressuring Health Canada to establish a more effective system for reporting and monitoring adverse drug reactions. In 2003, Health Canada established a Marketed Health...

  • Health Canada Fears Drugs in Water Supply.  // Natural Life;Nov/Dec2001, Issue 82, p28 

    Reports on the concerns of Health Canada on the penetration of drugs in water supply. Announcement on the launching of research initiatives on minimization of risks; Plans to review products regulated by the Food and Drugs Act; Presence of drugs in the Canadian drinking water.

  • Experience briefs.  // Formulary;Oct96, Vol. 31 Issue 10, p949 

    Describes how enhancements made to an adverse drug reactions (ADR) program increased the number of ADRs reported and improved patient care. Enhancing the ADR reporting program; Defining ADR criteria; Designation of responsible person for ADR program; Simplifying the ADR reporting process;...

  • Alemtuzumab: infection-related deaths.  // WHO Drug Information;2008, Vol. 22 Issue 4, p288 

    The article reports on the warning of Health Canada regarding the side effect of alemtuzumab, a recombinant humanized monoclonal antibody and commercially known as Mabcampath, in cancer consolidation therapy along with other chemotherapeutic and biologic agents. It discusses the results of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics